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Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown
superiority compared to chemotherapy alone as first-line therapy in advanced non–small
cell lung carcinoma (NSCLC). To evaluate the relative benefit in term of Overall Survival
(OS) and Progression-free Survival (PFS) of checkpoint inhibitors plus chemotherapy vs.
chemotherapy alone, overall and in subgroups defined by PDL1 expression we have
performed a meta-analysis.
Data Sources: This meta-analysis searched PubMed and checked references of the
selected English language articles to identify further eligible trials. Data collection for this
study took place from October 1 to October 24, 2018.
Results: In total, 8 trials involving 4,646 patients with advanced NSCLC, 3.314 (71%)
and 1.332 (29%) with a non-squamous and squamous histology, respectively, were
included in this meta-analysis. Four trials used atezolizumab, 3 pembrolizumab, and
1 nivolumab, accounting for 2.985 (64%), 1.298 (28%), and 363 (8%) of patients,
respectively. The patients were randomized to receive first-line chemotherapy plus a
checkpoint inhibitor vs. first-line chemotherapy, 2,978 patients for the OS endpoint
and first-line chemotherapy plus a checkpoint inhibitor vs. first-line chemotherapy,
1,740 patients in the PFS endpoint. Checkpoint inhibitors plus chemotherapy were
associated with prolonged OS, compared with chemotherapy in the ITT population
(HR, 0.74; 95% CI, 0.64–0.87; p = 0.0002, with significant heterogeneity among trials).
Notably within the PDL1 low group (1–49) there was a significant heterogeneity (p
= 0.06) between type of drug and efficacy: the combination of chemotherapy plus
pembrolizumab showed an OS benefit (HR, 0.56; 95% CI, 0.40–0.78; P < 0.00007)
unlike the atezolizumab backbone trials (HR, 0.92; 95% CI, 0.62–1.37; P < 0.69).
However, checkpoint inhibitors plus chemotherapy were associated with prolonged PFS
in the ITT (HR, 0.61; 95% CI, 0.56–0.66; P < 0.00001) and across PDL1 subgroups.
Addeo et al. First Line Treatment in NSCLC
Conclusion and Relevance: Checkpoint inhibitors plus chemotherapy compared
with chemotherapy, are associated with significantly prolonged OS and PFS in first-line
therapy in NSCLC. In the low PDL1 subgroups the benefit was statistically significant only
in the pembrolizumab backbone trials. The findings of this meta-analysis could assist in
the design and interpretation of future trials and in economic analyses.
Keywords: NCSLC, checkpoint inhibition, first line, PDL1, PD1
INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide.
Non-small-cell lung cancer (NSCLC) accounts for almost 85%
of all cases (1). The prognosis of NSCLC patients remains
quite unsatisfactory despite significant progress in the past few
years (2, 3). Inhibitors of programmed death-1 (PD-1) and its
ligand PD-L1 have proven to be effective therapies in metastatic
NSCLC lacking sensitizing EGFR or ALK mutations, initially as
second-line therapy (4–8). Subsequently, in metastatic NSCLC
patients with PD-L1 expression of at least 50% on tumor
cells, upfront pembrolizumab improvedmedian progression-free
survival (PFS) and overall survival (OS) compared to standard
platinum-based chemotherapy (9). However, patients with a
tumor proportion score (TPS) of 50% or greater represent only
20–30% of those with NSCLC (10). To enhance the immune
response through PD-1 inhibition, several studies have combined
the potential immunogenic effects of cytotoxic chemotherapy
with immune checkpoint inhibitors (ICPI). The first study that
gave some important information regarding the efficacy of
combining IO and chemotherapy (CH) was Keynote 021 (11):
a randomized phase II trial of carboplatin plus pemetrexed
with and without pembrolizumab. It showed significantly better
response rates (RR) and longer PFS with the addition of
pembrolizumab to chemotherapy. Several subsequent studies
have been published and presented at international conferences,
showing a benefit in terms of PFS and/or OS in the intention-to-
treat (ITT) population. However, due to the trials’ design, where
subgroup analysis by PD-L1 breakdown was mainly exploratory,
the question about the magnitude of benefit in the three main
different subgroups (PD-L1 negative, low or high) has remained
rather uncertain.
We have therefore conducted a meta-analysis to compare the
PFS and OS of chemotherapy plus ICPI vs. chemotherapy in
the ITT population and within the three principal subgroups of
PD-L1 expression (negative, low or high).
MATERIALS AND METHODS
Evidence Acquisition
Identification of Eligible Trials
A PubMed literature search was performed in October 2018 and
updated the 24th of October 2018, to identify all randomized
trials testing the addition of an antiPD-1 or antiPD-L1 ICPI
to first-line platinum-based chemotherapy in patients with
NSCLC. The following key-words were used: (non-small cell lung
cancer) AND nivolumab OR pembrolizumab OR atezolizumab OR
avelumab OR durvalumab) AND (random∗). References of the
selected articles were also checked to identify other eligible trials.
Furthermore, proceedings of the main international meetings
(American Society of Clinical Oncology [ASCO] annual meeting,
European Society of Medical Oncology [ESMO] annual meeting,
International Association for the Study of Lung Cancer [IASLC]
World Conference on Lung Cancer), were searched from 2010
onwards for relevant abstracts. Both trials enrolling patients
with tumor histology (squamous and non-squamous) and trials
enrolling only patients with one type of histology were eligible.
Trials with treatment arms including a targeted agent (e.g.,
bevacizumab) in addition to platinum-based chemotherapy and
trials with a maintenance phase (e.g., pemetrexed) after the
completion of platinum-based chemotherapy were considered
eligible for the analysis. When more than one report was
available for the same clinical trial, the most recent information
(corresponding to longer follow-up and higher number of events)
was considered in the analysis.
Data Collection
We have collected aggregate data from publications or
presentations at meetings and for each eligible trial, the
following data were extracted, if available:
• main inclusion criteria: age, performance status,
stage, histology;
• details of study treatment: type of platinum-based
chemotherapy (drugs, doses, and number of cycles), type
of ICPI (drug, dose, and duration of treatment);
• study design: primary endpoint, study hypothesis;
• patient enrolment and follow-up: accrual start and end
date; number of patients assigned to the experimental arm
(chemotherapy + ICPI), number of patients assigned to the
control arm (chemotherapy alone), median follow-up;
• OS: number of deaths in each arm, median OS, hazard ratio
with 95% confidence interval, p-value, details of subgroup
analysis according to PD-L1 expression (negative expression;
low expression; high expression);
• PFS: number of events in each arm, median PFS, hazard ratio
with 95% confidence interval, p-value, details of subgroup
analysis according to PD-L1 expression (negative expression;
low expression; high expression).
Low PD-L1 expression was defined as PD-L1 TPS of 1–49%
in the trials with pembrolizumab or PD-L1 expression on 1–
49% of tumor cells (TC) or 1–9% of tumor-infiltrating immune
cells (IC) in the trials with atezolizumab. High PD-L1 expression
was defined as PD-L1 TPS of 50% or greater in the trials with
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pembrolizumab or PD-L1 expression of 50% or greater on TC or
10% or greater IC in the trials with atezolizumab.
Statistical Methods
After data were abstracted, analysis was performed with the
Review Manager (RevMan 5.3) software. In all the 8 trials
included (11–20), efficacy data were analyzed from all randomly
assigned patients on an ITT basis. The primary endpoint of the
meta-analysis was OS. The secondary endpoint was PFS.
For both OS and PFS, the summary measure was the
hazard ratio (with 95% confidence interval). A random-effects
model was applied. Statistical heterogeneity among studies
was examined using the χ 2 test and the I2 statistic, which
expresses the percentage of the total observed variability due to
study heterogeneity.
One trial (16, 17) had two experimental arms adding an
ICPI to chemotherapy, the first testing the combination of
carboplatin+ paclitaxel, bevacizumab and atezolizumab, and the
second testing the combination of carboplatin + paclitaxel and
atezolizumab, vs. the same control armwithout ICPI (carboplatin
+ paclitaxel + bevacizumab). We decided to include both
comparisons in the meta-analysis. However, since that trial used
the same control arm for the two comparisons, the weight of each
comparison was reduced according to a correction factor: the
standard error for each comparison was multiplied by the square
root of (2+1)/2)= 1.225. This correction resulted in a prudential
increase in the width of the confidence interval for the estimated
hazard ratio of each comparison.
The subgroup analysis of patients according to PD-L1
expression was available for 5 trials (12, 14–16, 19) for OS
and 8 trials (11, 12, 14–16, 18–20) for PFS. In the KEYNOTE-
021 trial (11), information about subgroup analysis of PFS
was available for patients with absent PD-L1 expression and
for patients with high PD-L1 expression, but not for patients
with low PD-L1 expression. In the CheckMate 227 trial (20)
the comparison between chemotherapy + immune checkpoint
inhibitor vs. chemotherapy alone was conducted only in the
subgroup of cases with no PD-L1 expression, so this trial was
considered only in this subgroup analysis.
For both OS and PFS, in the whole population and in
the subgroup analysis according to PD-L1 expression, the
heterogeneity among the subsets of trials with different immune
checkpoint inhibitors was assessed using an interaction test. The
null hypothesis that the efficacy of the addition of immune
checkpoint inhibitor to chemotherapy is equal with different
drugs was tested with a χ2 test.
Role of Funding Source
There was no funding source for this systematic review and
meta-analysis. All authors had full access to all the data and the
corresponding author (Alfredo Addeo) had final responsibility
for the decision to submit for publication.
RESULTS
Characteristics and Quality of the Trials
The selection process of trials eligible for the meta-analysis is
reported in Supplemental Figure 1. In the search updated on
October 24th 2018, out of the 273 papers published in extenso,
270 were excluded, while three were found eligible for inclusion
(11, 12, 16). Five further eligible trials were found searching the
proceedings of the main international meetings (14, 15, 17–20).
The main characteristics of the eight available trials are
described in Table 1. Considering all the selected trials, 4,646
patients were included, 3,314 (71%) and 1,332 (29%) with
a non-squamous and squamous histology, respectively. Five
trials were with atezolizumab, 3 were with pembrolizumab and
1 with nivolumab, accounting for 2,985 (64%), 1,298 (28%),
and 363 (8%) patients, respectively. Chemotherapy regimens
included platinum-pemetrexed for 1,590 patients (34%) with
non-squamous histology, carboplatin-(nab)-paclitaxel (with the
possible addition of bevacizumab in non-squamous) for 2,966
patients (64%) with both histology, and platinum-gemcitabine
for 90 patients (2%) with squamous histology.
Patient Characteristics
Overall, 4,620 patients were enrolled in the 8 trials included
in the meta-analysis (OS comparison in the whole population),
2,542 (55.0%) assigned to platinum-based chemotherapy+ ICPI,
and 2,078 (45.0%) assigned to platinum-based chemotherapy
alone (Table 1 and Figure 1A). In addition, 363 patients enrolled
in the CheckMate 227 trial (20) were considered only for the
PFS comparison in the subgroup of cases with negative PD-
L1 expression (Table 1 and Figure 2C). Main characteristics
of the enrolled patients are described in Table 2. For 4 trials
the enrolment period was available, and patients were enrolled
between November 2014 and March 2017. Median age was 62.5–
65 years and all patients had a 0 or 1 Eastern Cooperative
Oncology Group (ECOG) performance status (PS), with the
proportion of patients with PS 0 and 1 ranging from 31 to
60% and 40 to 64%, respectively. Information about PD-L1
expression was available for 3,808 of the 3,862 evaluable patients
(99%). With the exception of the CheckMate 227 study (20),
which was restricted to those with negative PD-L1 expression,
the proportion of patients with negative PD-L1 expression
ranged from 31 to 37% and 47 to 53% for patients enrolled
in trials with pembrolizumab or atezolizumab, respectively. The
proportion of patients with low PD-L1 expression ranged from
28 to 37% and 28 to 38% in studies with pembrolizumab and
atezolizumab, respectively. The proportion of patients with high
PD-L1 expression ranged from 26 to 34% and 14 to 20% for trials
with pembrolizumab and atezolizumab, respectively.
Overall Survival
In the whole study population (N = 4.620), as shown
in Figure 1A, the addition of an ICPI to platinum-based
chemotherapy in patients with metastatic NSCLC was associated
with a statistically significant benefit in overall survival (hazard
ratio [HR] 0.74, 95% confidence interval [CI] 0.64–0.87,
p = 0.0002). There was evidence of statistically significant
heterogeneity among the 8 comparisons (p = 0.005, I² = 66%).
HR was equal to 0.85 (95% CI 0.76–0.94, p = 0.001) in the
trials with atezolizumab, and equal to 0.56 (95% CI 0.46–0.67,
p < 0.00001) in the trials with pembrolizumab, with statistically
significant quantitative interaction between type of drug and
treatment efficacy (interaction p< 0.0001; see Figure 1B).
Frontiers in Oncology | www.frontiersin.org 3 April 2019 | Volume 9 | Article 264
Addeo et al. First Line Treatment in NSCLC
TABLE 1 | Main characteristics of the selected studies.
Trial
reference
Drug Phase no. pts Histology PD-L1 FU
time
median
mo.
HR OS
(95% CI)
P-value
HR PFS
(95% CI)
P-value
KN-189 (1) Pembrolizumab ±
Platinum-Pem
III
616
NonSq any 10.5 0.49
(0.38–0.64)
<0.001
0.52
(0.43–0.64)
<0.001
KN-021 (2, 3) Pembrolizumab ±
Carbo-Pem
II
123
NonSq any 10.6 0.90
(0.42–1.91)
0.39
0.53
(0.31–0.91)
0.010
KN-407a (4) Pembrolizumab ±
Carbo-(nab)Pac
III
559
Sq any 7.7 0.64
(0.49–0.85)
0.0008
0.56
(0.45–0.70)
<0.0001
IMPower131 (5)a Atezolizumab ±
Carbo-nabPac
III
683
Sq any 9.8b 0.96
(0.78–1.18)
0.69
0.71
(0.60–0.85)
0.0001
IMPower150 (6) Atezolizumab ±
Carbo-Pac-Beva
III
696
NonSq any 15.5 0.78a
(0.64–0.96)
P = 0.02
0.62
(0.52–0.74)
P < 0.001
IMPower150bis (7) Atezolizumab +
Carbo-Pac vs.
Carbo-Pac-Beva
III
686c
NonSq any 20.0 NR 0.88 a
(0.72-1.08)
0.20
IMPower132 (8)a Atezolizumab ±
Platinum-Pem
III
578
NonSq any NR 0.81
(0.64–1.03)
p = 0.08
0.60
(0.49–0.72)
P < 0.0001
IMPower130 (9) Atezolizumab ±
Carbo-nabPac
III
679
NonSq any 13.0b 0.79
(0.64–0.98)
0.03
0.64
(0.54–0.77)
<0.0001
CM-227 (10) Nivolumab ±
Platinum-Pem
in NonSq
Platinum-Gem
in Sq
III
363
NonSq (273)
Sq
(90)
<1% 11.2b NR 0.74
(0.58–0.94)
P = NR
Beva, bevacizumab; Carbo, carboplatin; CM, Checkmate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICPIs, immune-checkpoint inhibitors; CTRT, chemo-
radiotherapy; FU, follow-up; KN, Keynote; mo., months; NonSq, non-squamous; NR, not reported; NSCLC, non-small cell lung cancer; Pem, pemetrexed; Pac, paclitaxel; Sq, squamous;
vs. versus.
aResults refer to first interim analysis.
bMinimum follow-up.
cCarbo-Pac-Beva arm was the same of the above mentioned trial and included 337 patients.
In the subgroup of patients with negative PD-L1 expression
(N = 1.413, data available for 5 trials), as shown in Figure 1C,
the addition of an ICPI to platinum-based chemotherapy in
patients withmetastatic NSCLCwas associated with a statistically
significant benefit in OS (HR 0.78, 95% CI 0.67–0.90, p
= 0.0007). There was no evidence of statistically significant
heterogeneity among the 5 trials (p = 0.52, I² = 0%). HR
was equal to 0.83 (95% CI 0.71–0.98, p = 0.03) in the 3 trials
with atezolizumab, and equal to 0.60 (95% CI 0.43–0.83, p
= 0.002) in the 2 trials with pembrolizumab, with evidence
of a borderline statistically significant quantitative interaction
between type of drug and treatment efficacy (interaction p= 0.08;
see Figure 3A).
In the subgroup of patients with low PD-L1 expression (N
= 1,062, data available for 5 trials), as shown in Figure 1D,
the addition of an ICPI to platinum-based chemotherapy in
patients with metastatic NSCLC was not associated with a
statistically significant benefit in OS (HR 0.77, 95% CI 0.55–
1.07, p = 0.12). There was evidence of statistically significant
heterogeneity among the 5 trials (p = 0.01, I² = 70%).
HR was equal to 0.92 (95% CI 0.62–1.37, p = 0.69) in
the 3 trials with atezolizumab, and equal to 0.56 (95% CI
0.40–0.78, p = 0.0007) in the 2 trials with pembrolizumab,
with evidence of statistically significant quantitative interaction
between type of drug and treatment efficacy (interaction p= 0.06;
see Figure 3B).
In the subgroup of patients with high PD-L1 expression
(N = 714, data available for 5 trials), as shown in Figure 1E,
the addition of an ICPI to platinum-based chemotherapy in
patients withmetastatic NSCLCwas associated with a statistically
significant benefit in OS (HR 0.61, 95%CI 0.48–0.78, p< 0.0001).
There was no evidence of statistically significant heterogeneity
among the 5 trials (p = 0.36, I² = 7%). HR was equal to 0.70
(95% CI 0.52–0.94, p = 0.02) in the 3 trials with atezolizumab,
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FIGURE 1 | Overall survival with chemotherapy plus ICPIs. (A) OS in whole study population. (B) OS by ICPI administered. (C) OS by PD-L1 expression- PD-L1
negative. (D) OS by PD-L1 expression- PD-L1 low. (E) OS by PD-L1 expression- PD-L1 high.
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FIGURE 2 | Progression-free survival with chemotherapy plus ICPI. (A) PFS in whole study population. (B) PFS by ICPI administered. (C) PFS by PD-L1 expression-
PD-L1 negative. (D) PFS by PD-L1 expression - PD-L1 low. (E) PFS by PD-L1 expression- PD-L1 high.
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TABLE 2 | Main characteristics of enrolled patients.
Trial
reference
Arm
(accrual period)
No. pts Age, yr,
median
ECOG PS 0,
1, 2
(%)
PD-L1
NE
(%)
PD-L1a
neg, low, high
(%)
KN-189 (1) Pembro-Combo vs.
Placebo-Combo
(02/2016-03/2017)
410
206
65
63.5
45, 54, 0.2
39, 61, 0
6
7
31, 31, 32
31, 28, 34
KN-021 (2, 11) Pembro-Chemo vs.
Chemo
(11/2014-01/2016)
60
63
62.5
63
40, 58, 0
46, 54, 0
0
0
35, 32, 33
37, 37, 27
KN-4074 Pembro-Chemo vs.
Placebo-Chemo
(NR)
278
281
65
65
26, 74, 0
32, 68, 0
2.5
2
34, 37, 26
35, 37, 26
IMPower131 (5) Atezo-Chemo vs.
Chemo
(NR)
343
340
65
65
34, 66, 0
32, 68, 0
0.3
0
47, 38, 15
50, 36, 14
IMPower150 (6) Atezo-Chemo-Beva vs.
Chemo-Beva
(03/2015-12/2016)
400
400
63
63
40, 60, 0
45, 55, 0
0
0
48, 33, 19
51, 31, 18
IMPower150bis (7) Atezo-Chemo vs.
Chemo-Beva
(03/2015-12/2016)
402
400
63
63
45, 55, 0
45, 55, 0
0.2
0
47, 36, 17
51, 31, 18
IMPower132 (8) Atezo-Chemo
Placebo-Chemo
(NR)
292
286
64
63
43, 57, 0
40, 60,0
NR
NR
NR
NR
IMPower130 (9) Atezo-Chemo
Placebo-Chemo
(NR)
451
228
NR
NR
58, 42, 0
60, 40, 0
0
0
52, 28, 20
53, 29, 18
CM-227 (10)b Nivo-Chemo vs.
Chemo
(NR)
177
186
64
64
33, 66, NR
31, 68, NR
NA
NA
100, 0, 0
100, 0, 0
Atezo, atezolizumab; Beva, bevacizumab; Carbo, carboplatin; Chemo, chemotherapy; ECOGPS, Eastern Cooperative Oncology Group Performance Status; IC, tumor-infiltrating immune
cell; ICPIs, immune-checkpoint inhibitors; NA, not applicable; NE, not evaluated; neg, negative; NR, not reported; Nivo, nivolumab; Pembro, pembrolizumab; vs, versus; TC, tumor cell.
aFor Pembro, negative = <1%, low = 1-49%, high ≥ 50% by the use of the 22C3 pharmDx assay (Agilent); for Atezo, negative = TC0 and IC0; low = TC 1/2 or IC 1/2; high = TC3 or
IC3 by the use of the SP142 PD-L1 immunohistochemistry assay (Ventana Medical Systems).
bStudy results restricted to patients with <1% PD-L1 expression.
and equal to 0.51 (95% CI 0.34–0.77, p = 0.001) in the 2 trials
with pembrolizumab, with no evidence of interaction between
type of drug and treatment efficacy (interaction p = 0.21;
see Figure 3C).
Progression-Free Survival
In the whole study population (N = 3.930, data available for
7 trials), as shown in Figure 2A, the addition of an ICPI
to platinum-based chemotherapy in patients with metastatic
NSCLC was associated with a statistically significant benefit in
PFS(HR 0.61, 95% CI 0.56–0.66, p < 0.00001). There was no
evidence of statistically significant heterogeneity among the 7
trials (p = 0.37, I² = 8%). HR was equal to 0.64 (95% CI
0.59–0.70, p < 0.00001) in the 4 trials with atezolizumab, and
equal to 0.54 (95% CI 0.47–0.62, p < 0.00001) in the 3 trials
with pembrolizumab, with evidence of quantitative interaction
between type of drug and treatment efficacy (interaction p= 0.04;
see Figure 2B).
In the subgroup of cases with negative PD-L1 expression (N
= 1,864, data available for 8 trials), as shown in Figure 2C,
the addition of an ICPI to platinum-based chemotherapy in
patients withmetastatic NSCLCwas associated with a statistically
significant benefit in PFS (HR 0.73, 95% CI 0.66–0.82, p <
0.00001). There was no evidence of statistically significant
heterogeneity among the 8 trials (p = 0.46, I² = 0%). HR
was equal to 0.75 (95% CI 0.66–0.86, p < 0.0001) in the
4 trials with atezolizumab, equal to 0.63 (95% CI 0.44–0.92,
p = 0.02) in the 3 trials with pembrolizumab, and equal
to 0.74 (95% CI 0.58–0.94, p = 0.02) in the trial with
nivolumab, without evidence of significant interaction between
type of drug and treatment efficacy (interaction p = 0.69;
see Figure 4A).
In the subgroup of patients with low PD-L1 expression (N
= 1,196, data available for 6 trials), as shown in Figure 2D,
the addition of an ICPI to platinum-based chemotherapy in
patients withmetastatic NSCLCwas associated with a statistically
significant benefit in PFS (HR 0.63, 95% CI 0.55–0.72, p <
0.00001). There was no evidence of statistically significant
heterogeneity among the 6 trials (p = 0.60, I² = 0%). HR was
equal to 0.66 (95% CI 0.56–0.77, p < 0.00001) in the 4 trials
with atezolizumab, and equal to 0.56 (95% CI 0.43–0.72, p <
0.0001) in the 2 trials with pembrolizumab, without evidence
of significant interaction between type of drug and treatment
efficacy (interaction p= 0.29; see Figure 4B).
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FIGURE 3 | Overall survival by ICPI drug according to PD-L1 expression. (A) OS in PO-L1 negative population. (B) OS in PO-L1 low population. (C) OS in PO-L1 high
population.
In the subgroup of patients with high PD-L1 expression
(N = 913, data available for 7 trials), as shown in Figure 2E,
the addition of an ICPI to platinum-based chemotherapy in
patients withmetastatic NSCLCwas associated with a statistically
significant benefit in PFS (HR 0.43, 95% CI 0.37–0.51, p <
0.00001). There was no evidence of statistically significant
heterogeneity among the 7 trials (p = 0.60, I² = 0%). HR was
equal to 0.45 (95% CI 0.36–0.55, p < 0.00001) in the 4 trials
with atezolizumab and equal to 0.42 (95% CI 0.30–0.60, p <
0.00001) in the 3 trials with pembrolizumab, without evidence
of significant interaction between type of drug and treatment
efficacy (interaction p= 0.77; see Figure 4C).
DISCUSSION
In the present meta-analysis of all published and presented
randomized clinical trials with PD-1 and PD-L1 inhibitors plus
chemotherapy as first-line treatment for patients with metastatic
NSCLC, we observed a clear benefit in OS and PFS in the ITT
population with the addition of ICPI to chemotherapy.
We addressed the question regarding the benefit of
chemotherapy plus ICPI in terms of OS and PFS in all
different PD-L1 expression subgroups. Furthermore, to extend
the analysis, we also explored the possible difference in terms of
OS and PFS by grouping trials by anti-PD-1 or anti-PD-L1 drugs.
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FIGURE 4 | Progression-free survival by ICPI drug according to PD-L1 expression. (A) PFS in PO-L1 negative population. (B) PFS in PO-L1 low population. (C) PFS
in PO-L1 high population.
As shown in the results, there is a PFS advantage of
ICPI plus chemotherapy over chemotherapy alone both in the
ITT population and in the different subgroups according to
PD-L1 expression and type of drug. However, while the OS
benefit is found in the overall ITT population, it does not
reach statistical significance in the ITT PD-L1 low expression
population. Significant heterogeneity appears in the ITT ICPI
subgroup analysis in favor of the anti-PD-1 ICPI pembrolizumab.
Furthermore, along with the clear OS advantage observed
with the addition of ICPIs to chemotherapy in the ITT
population and in the PD-L1 high subgroup of patients, when
examining the heterogeneity between different drugs the HRs
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are more beneficial with the anti-PD-1 pembrolizumab than
with the anti-PD-L1 atezolizumab in the ITT and in the PD-
L1 negative and low expression subgroup of patients. This
evidence suggests the benefit in OS is, at least currently,
strongly driven by the Keynote trials (11–14), with at least three
possible explanations.
The first relies on the more mature data and longer follow-up
of Keynote trials with pembrolizumab, of which two (11, 12) out
of three (11–14) were already published in extenso, as compared
with the Impower studies with atezolizumab, fromwhich data are
mainly preliminary. (15–19). Hence, data might change one way
or another during the next 12–18months, requiring confirmation
with longer follow-up as soon as the final results are published.
The second aspect pertains to the reliability of the
immunohistochemistry testing and scoring used in the Impower
trials to identify and stratify patients according to their PD-L1
tumor expression. This aspect has been extensively assessed in
the Blueprint phase 1 project (BP1) which clearly showed that
three PD-L1 assays (22C3, 28-8, and SP263) had comparable
analytical performance for assessment of PD-L1 expression on
tumor cells (TCs), whereas the SP-142 PD-L1 assay appeared to
stain fewer TCs compared with the other (21) assays. In contrast,
all the assays stained tumor-infiltrating immune cells (ICs), but
with poor concordance between assays. These findings were
further confirmed in the Bluprint phase 2 project >(BP2) (22),
which consolidates the analytical evidence for interchangeability
of the 22C3, 28-8, and SP263 assays and lower sensitivity of
the SP142 assay for determining tumor proportion score on
TCs. Moreover, we have highlighted a clear difference in the
proportion of patients in negative and high PD-L1 expression
subgroups, and a heterogeneity in the low PD-L1 expression
subgroup comparing pembrolizumab backbone trials and
Atezolizumab backbone ones. This, once again, confirms the
essential role of the platform used for testing PD-L1 and raises
the question of whether a companion diagnostic should be
preferred to reliably reproduce the benefits reported by clinical
trials in clinical practice.
The third aspect, perhaps more provocative but at the same
time fascinating, is the possibility that there was a real difference
in efficacy between anti-PD-1 and anti-PD-L1 drugs, or at
least between pembrolizumab and atezolizumab. Depending
on results after a longer follow-up, this may warrant further
exploration in a hypothetical randomized trial. There could also
be differences in the immunogenic activities of the chemotherapy
compounds combined with ICPI, as reported by Novosiadly
et al. (23), suggesting differently an immunomodulatory effect of
pemetrexed compared to paclitaxel. However, the magnitude of
the effect we observed in our analysis with the Keynote 407 trial,
which combined the anti-PD-1 pembrolizumab with paclitaxel
or nab-paclitaxel in squamous histology, appears similar to other
Keynote trial results.
Our study presents some limitations that we want to
acknowledge. First of all, this meta-analysis relies on published
results rather than on individual patients’ data, thus the results
from subgroup analysis are merely suggestive. Secondly, the
OS data from the included trials were not mature enough,
so the data might change in the future and, hence, updating
the meta-analysis with final OS data will be essential. A third
aspect is that only the Impower 150 recruited NSCLC patients
with activating EGFR mutation or ALK rearrangement, and
that used Bevacizumab as part of the backbone treatment. For
both aspects it is difficult to quantify the impact on our final
results analysis.
CONCLUSIONS
The results of this meta-analysis suggest that the combination
of chemotherapy plus ICPI, irrespective of histology and
PD-L1 expression, should be considered as the new
standard for patients with advanced NSCLC. Although
final results of most studies are needed to clarify the
effect of this treatment in the PD-L1 low expression
subgroup of patients, as well as possible differences between
different ICPIs, current data suggest a possible more
prominent OS advantage with the addition of anti-PD-1
pembrolizumab to chemotherapy, irrespective of the PD-L1 level
and histology.
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